


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the present application.

**Listing of Claims:**

Claim 1 (currently amended): A compound of structural formula I:



or a pharmaceutically acceptable salt thereof, wherein;

R<sup>1</sup> is selected from:

- (1) C<sub>1-10</sub>alkyl,
- (2) C<sub>3-10</sub>cycloalkyl,
- (3) cycloheteroalkyl,
- (4) aryl, and
- (5) heteroaryl,

wherein alkyl is optionally substituted with one, two, three or four substituents independently selected from R<sup>a</sup>, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are optionally substituted on a carbon or nitrogen atom with one, two, three or four substituents independently selected from R<sup>b</sup>;

R<sup>2</sup> is selected from:

- (1) C<sub>3-10</sub>cycloalkyl,
- (2) cycloheteroalkyl,
- (3) aryl,
- (4) heteroaryl,
- (5) -OR<sup>d</sup>,
- (6) -NR<sup>c</sup>R<sup>d</sup>, and
- (7) -CO<sub>2</sub>R<sup>d</sup>,

wherein each alkyl is optionally substituted with one, two, three or four substituents independently selected from  $R^a$ , and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are optionally substituted on a carbon or nitrogen atom with one, two, three or four substituents independently selected from  $R^b$ ;

$R^3$  is selected from:

- (1) hydrogen, and
- (2)  $C_{1-4}$ alkyl,

wherein alkyl is optionally substituted with one to four substituents independently selected from  $R^a$ ;

$R^6$  is selected from:

- (1) hydrogen,
- (2)  $C_{1-4}$ alkyl,
- (3)  $C_{2-4}$ alkenyl,
- (4)  $C_{2-4}$ alkynyl,
- (5)  $-OR^d$ ,
- (6) halogen,
- (7)  $-CN$ ,
- (8)  $-NR^cR^d$ ,

wherein alkyl, alkenyl, and alkynyl are optionally substituted with one to four substituents independently selected from  $R^a$

$Ar^1$  is selected from:

- (1) aryl, and
- (2) heteroaryl,

each optionally substituted on the carbon or nitrogen with one, two, or three groups independently selected from  $R^b$ ;

each  $R^a$  is independently selected from:

- (1)  $-OR^c$ ,
- (2)  $-NR^cS(O)_mR^d$ ,
- (3)  $-NO_2$ ,
- (4) halogen,
- (5)  $-S(O)_mR^c$ ,
- (6)  $-SR^c$ ,
- (7)  $-S(O)_2OR^c$ ,
- (8)  $-S(O)_mNR^cR^d$ ,

- (9)  $-NR^cR^d$ ,
- (10)  $-O(CR^eR^f)_nNR^cR^d$ ,
- (11)  $-C(O)R^c$ ,
- (12)  $-CO_2R^c$ ,
- (13)  $-CO_2(CR^eR^f)_nCONR^cR^d$ ,
- (14)  $-OC(O)R^c$ ,
- (15)  $-CN$ ,
- (16)  $-C(O)NR^cR^d$ ,
- (17)  $-NR^cC(O)R^d$ ,
- (18)  $-OC(O)NR^cR^d$ ,
- (19)  $-NR^cC(O)OR^d$ ,
- (20)  $-NR^cC(O)NR^cR^d$ ,
- (21)  $-CR^c(N-OR^d)$ ,
- (22)  $CF_3$ ,
- (23)  $-OCF_3$ ,
- (24)  $C_{3-8}cycloalkyl$ ,
- (25)  $cycloheteroalkyl$ , and
- (26)  $oxo$ ;

each  $R^b$  is independently selected from:

- (1)  $R^a$ ,
- (2)  $C_{1-10}alkyl$ ,
- (3)  $C_{3-8}cycloalkyl$ ,
- (4)  $cycloheteroalkyl$ ,
- (5)  $aryl$ ,
- (6)  $arylC_{1-4}alkyl$ ,
- (7)  $heteroaryl$ , and
- (8)  $heteroarylC_{1-4}alkyl$ ,

wherein  $alkyl$ ,  $cycloalkyl$ ,  $cycloheteroalkyl$ , and  $heteroaryl$  are optionally substituted with  $oxo$ , and

wherein  $aryl$  and  $heteroaryl$  are optionally substituted with  $-OR^c$ ,  $NR^cR^d$ , or  $-C(O)R^c$ ;

$R^c$  and  $R^d$  are independently selected from:

- (1)  $hydrogen$ ,
- (2)  $C_{1-10}alkyl$ ,
- (3)  $C_{2-10}alkenyl$ ,

- (4) C<sub>2-10</sub>alkynyl,
- (5) cycloalkyl,
- (6) cycloalkyl-C<sub>1-10</sub>alkyl,
- (7) cycloheteroalkyl,
- (8) cycloheteroalkyl-C<sub>1-10</sub>alkyl;
- (9) aryl,
- (10) heteroaryl,
- (11) aryl-C<sub>1-10</sub>alkyl, and
- (12) heteroaryl-C<sub>1-10</sub>alkyl, or

R<sup>c</sup> and R<sup>d</sup> together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R<sub>g</sub>, or two -OR<sup>c</sup> groups together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R<sub>g</sub>, each R<sup>c</sup> and R<sup>d</sup> may be unsubstituted or substituted with one to three substituents selected from R<sup>h</sup>;

R<sup>e</sup> and R<sup>f</sup> are independently selected from:

- (1) hydrogen,
- (2) C<sub>1-10</sub>alkyl,
- (3) C<sub>2-10</sub>alkenyl,
- (4) C<sub>2-10</sub>alkynyl,
- (5) cycloalkyl,
- (6) cycloalkyl-C<sub>1-10</sub>alkyl,
- (7) cycloheteroalkyl,
- (8) cycloheteroalkyl-C<sub>1-10</sub>alkyl,
- (9) aryl,
- (10) heteroaryl,
- (11) aryl-C<sub>1-10</sub>alkyl, and
- (12) heteroaryl-C<sub>1-10</sub>alkyl, or

R<sup>e</sup> and R<sup>f</sup> together with the carbon to which they are attached form a ring of 5 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

each R<sub>g</sub> is independently selected from

- (1) C<sub>1-10</sub>alkyl,
- (2) C<sub>3-8</sub>cycloalkyl,
- (3) cycloheteroalkyl,

- (4) aryl,
- (5) arylC<sub>1-4</sub>alkyl,
- (6) heteroaryl,
- (7) heteroarylC<sub>1-4</sub>alkyl,
- (8) -S(O)<sub>m</sub>Re,
- (9) -C(O)Re,
- (10) -CO<sub>2</sub>Re,
- (11) -CO<sub>2</sub>(CReR<sup>f</sup>)<sub>n</sub>CONReR<sup>f</sup>, and
- (12) -C(O)NReR<sup>f</sup>;

each R<sup>h</sup> is independently selected from:

- (1) C<sub>1-10</sub>alkyl,
- (2) C<sub>3-8</sub>cycloalkyl,
- (3) cycloheteroalkyl,
- (4) aryl,
- (5) arylC<sub>1-4</sub>alkyl,
- (6) heteroaryl,
- (7) heteroarylC<sub>1-4</sub>alkyl,
- (8) -ORE,
- (9) -NReS(O)<sub>m</sub>R<sup>f</sup>,
- (10) -S(O)<sub>m</sub>Re,
- (11) -SRe,
- (12) -S(O)<sub>2</sub>ORE,
- (13) -S(O)<sub>m</sub>NReR<sup>f</sup>,
- (14) -NReR<sup>f</sup>,
- (15) -O(CReR<sup>f</sup>)<sub>n</sub>NReR<sup>f</sup>,
- (16) -C(O)Re,
- (17) -CO<sub>2</sub>Re,
- (18) -CO<sub>2</sub>(CReR<sup>f</sup>)<sub>n</sub>CONReR<sup>f</sup>,
- (19) -OC(O)Re,
- (20) -CN,
- (21) -C(O)NReR<sup>f</sup>,
- (22) -NReC(O)R<sup>f</sup>,
- (23) -OC(O)NReR<sup>f</sup>,

- (24)  $-NR^eC(O)OR^f$ ,
- (25)  $-NR^eC(O)NR^eR^f$ ,
- (26)  $CF_3$ , and
- (27)  $-OCF_3$ ,

m is selected from 1 and 2; and

n is selected from 1, 2, and 3;

~~provided that when  $R^1$  is phenyl, naphthyl, or heteroaryl,  $R^2$  is phenyl and  $R^3$  is hydrogen, then  $Ar^1$  is not unsubstituted phenyl and is not mono, di or tri-substituted phenyl with an  $R^b$ -substituent selected from the group consisting of halogen, hydroxy,  $C_{1-6}$ -alkyl, phenyl, CN,  $NO_2$ ,  $CO_2H$ ,  $C(O)C_{1-6}$ -alkyl,  $CO_2C_{1-6}$ -alkyl,~~

~~$-C(O)NH_2$ ,  $-C(O)NH$ -heterocycloalkyl,  $NH_2$ ,  $NH$ -heterocycloalkyl, furanyl, dihydrofuranyl, pyrrolidyl, dihydropyrrolidyl, and 1,3-dioxolan; and~~

~~provided that when  $R^1$  is aryl, monosubstituted with halogen,  $OCH_3$  or  $CH_3$  or optionally di-substituted with halogen,  $R^2$  is aryl, optionally mono or di-substituted with halogen, and  $R^3$  is hydrogen, then  $Ar^1$  is not unsubstituted 4-pyridinyl; and~~

~~provided that when  $R^1$  and  $R^2$  are unsubstituted aryl or unsubstituted heteroaryl, and  $R^3$  is hydrogen or  $C_{1-4}$ -alkyl, then  $Ar^1$  is substituted with at least one  $R^b$  substituent; and~~

provided that when  $R^1$  is selected from the group consisting of unsubstituted phenyl, *para*-chlorophenyl or *para*-methoxy phenyl,  $R^2$  is unsubstituted phenyl, and  $R^3$  is  $-CH_3$ , then  $Ar^1$  is not unsubstituted phenyl, *ortho*- $CO_2H$  monosubstituted phenyl, or 3,4-dimethoxy phenyl.

Claim 2 (currently amended): The compound according to Claim 1 wherein:

$R^1$  is selected from:

- (1)  $C_{1-10}$ -alkyl,
- (2)  $C_{3-10}$ -cycloalkyl,
- (3) cycloheteroalkyl,
- (4) aryl, and
- (5) heteroaryl,

wherein alkyl is optionally substituted with one, two, three or four substituents independently selected from  $R^a$ , and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from  $R^b$ ;

$R^2$  is selected from:

- (1) C<sub>3-10</sub>cycloalkyl,
- (2) cycloheteroalkyl,
- (3) aryl,
- (4) heteroaryl,
- (5) -OR<sup>d</sup>,
- (6) -NR<sup>c</sup>R<sup>d</sup>, and
- (7) -CO<sub>2</sub>R<sup>d</sup>,

~~wherein each alkyl is optionally substituted with one, two, three or four substituents independently selected from  $R^a$ , and each cycloalkyl, and cycloheteroalkyl aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from  $R^b$ ;~~

or a pharmaceutically acceptable salt thereof.

Claim 3 (Original): The compound according to Claim 2 wherein:

Ar<sup>1</sup> is selected from:

- (1) phenyl,
- (2) naphthyl,
- (3) thienyl,
- (4) furanyl,
- (5) pyrrolyl,
- (6) oxazolyl,
- (7) isoxazolyl,
- (8) 1,2,5-oxadiazolyl,
- (9) 1,2,5-thiadiazolyl,
- (10) thiazolyl,
- (11) pyrazolyl,
- (12) triazolyl,
- (13) tetrazolyl,
- (14) benzothienyl,
- (15) benzofuranyl,

- (16) benzoxazolyl,
- (17) benzimidazolyl,
- (18) benzothiazolyl,
- (19) indanyl,
- (20) indenyl,
- (21) indolyl,
- (22) imidazo[1,2-a]pyridinyl,
- (23)  $\beta$ -carbolinyl,
- (24) 5,6,7,8-tetrahydro- $\beta$ -carbolinyl,
- (25) tetrahydronaphthyl,
- (26) 4,5,6,7-tetrahydroindazolyl,
- (27) 2,3-dihydrobenzofuranyl,
- (28) dihydrobenzopyranyl,
- (29) 1,4-benzodioxanyl,
- (30) pyridinyl,
- (31) pyrimidinyl,
- (32) pyrazinyl,
- (33) quinolinyl,
- (34) isoquinolinyl,
- (35) quinazolonyl,
- (36) quinazolinyl,
- (37) 1,8-naphthyridinyl,
- (38) 1,2,3,4-tetrahydro-1,8-naphthyridinyl,
- (39) pyrido[3,2-b]pyridinyl,
- (40) pyrazolo[2,3-a]pyrimidinyl,
- (41) pyrido[1,2-a]pyrimidinyl,
- (42) pyrido[1,2-a]pyrimidonyl,
- (43) benzopyrimidinyl,
- (44) imidazolyl, and
- (45) imidazolonyl,

each optionally substituted with one, two, or three groups independently selected from R<sup>b</sup>;  
or a pharmaceutically acceptable salt thereof.



Claim 4 (Original): The compound according to Claim 3 wherein:

R<sup>3</sup> is C<sub>1-4</sub>alkyl, optionally substituted with one to four substituents independently selected from R<sup>a</sup>;

R<sup>6</sup> is selected from:

- (1) hydrogen,
- (2) methyl,
- (3) hydroxyl,
- (4) halogen, and
- (5) -CN,

wherein methyl is optionally substituted with one to three R<sup>a</sup> substituents;

Ar<sup>1</sup> is selected from:

- (1) phenyl,
- (2) naphthyl,
- (3) thienyl,
- (4) isoxazolyl,
- (5) 1,2,5-oxadiazolyl,
- (6) thiazolyl,
- (7) pyrazolyl,
- (8) triazolyl,
- (9) tetrazolyl,
- (10) benzofuranyl,
- (11) benzoxazolyl,
- (12) benzimidazolyl,
- (13) benzothiazolyl,
- (14) imidazo[1,2-a]pyridinyl,
- (15) 5,6,7,8-tetrahydro- $\beta$ -carbolinyl,
- (16) 4,5,6,7-tetrahydroindazolyl,
- (17) pyridinyl,
- (18) pyrimidinyl,
- (19) pyrazinyl,
- (20) quinolinyl,
- (21) isoquinolinyl,
- (22) quinazolonyl,
- (23) quinazolinyl,

- (24) 1,8-naphthyridinyl,
- (25) 1,2,3,4-tetrahydro-1,8-naphthyridinyl,
- (26) pyrido[3,2-b]pyridinyl,
- (27) pyrazolo[2,3-a]pyrimidinyl,
- (28) pyrido[1,2-a]pyrimidinyl,
- (29) pyrido[1,2-a]pyrimidonyl,
- (30) benzopyrimidinyl,
- (31) imidazolyl, and
- (32) imidazolonyl,

each optionally substituted with one, two, or three groups independently selected from R<sup>b</sup>;

each R<sup>a</sup> is independently selected from:

- (1) -OR<sup>c</sup>,
- (2) halogen,
- (3) -S(O)<sub>m</sub>R<sup>c</sup>,
- (4) -SR<sup>c</sup>,
- (5) -S(O)<sub>2</sub>OR<sup>c</sup>,
- (6) -S(O)<sub>m</sub>NR<sup>c</sup>R<sup>d</sup>,
- (7) -NR<sup>c</sup>R<sup>d</sup>,
- (8) -C(O)R<sup>c</sup>,
- (9) -CO<sub>2</sub>R<sup>c</sup>,
- (10) -CN,
- (11) -C(O)NR<sup>c</sup>R<sup>d</sup>,
- (12) CF<sub>3</sub>,
- (13) -OCF<sub>3</sub>,
- (14) C<sub>3-8</sub>cycloalkyl,
- (15) cycloheteroalkyl, and
- (16) oxo;

each R<sup>b</sup> is independently selected from:

- (1) R<sup>a</sup>,
- (2) C<sub>1-10</sub>alkyl,
- (3) cycloheteroalkyl,
- (4) aryl,
- (5) arylC<sub>1-4</sub>alkyl,

- (6) heteroaryl, and
- (7) heteroarylC<sub>1-4</sub>alkyl,

wherein alkyl, cycloalkyl, cycloheteroalkyl, heteroaryl are optionally substituted with oxo, and wherein aryl and heteroaryl are optionally substituted with -OR<sup>c</sup>, NR<sup>c</sup>R<sup>d</sup>, or -C(O)R<sup>c</sup>;

R<sup>c</sup> and R<sup>d</sup> are independently selected from:

- (1) hydrogen,
- (2) C<sub>1-10</sub>alkyl,
- (3) cycloalkyl,
- (4) cycloheteroalkyl,
- (5) aryl,
- (6) heteroaryl, or

R<sup>c</sup> and R<sup>d</sup> together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R<sub>g</sub>, or two -OR<sup>c</sup> groups together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R<sub>g</sub>, each R<sup>c</sup> and R<sup>d</sup> may be unsubstituted or substituted with one to three substituents selected from R<sub>h</sub>; or a pharmaceutically acceptable salt thereof.

Claim 5 (Original): The compound according to Claim 4 wherein:

R<sup>1</sup> and R<sup>2</sup> are independently selected from:

- (1) phenyl, and
- (2) pyridyl,

each optionally substituted with one to four substituents independently selected from R<sup>b</sup>;

R<sup>3</sup> is C<sub>1-4</sub>alkyl, wherein alkyl is optionally substituted with one to four substituents independently selected from R<sup>a</sup>;

R<sup>6</sup> is selected from:

- (1) hydrogen,
- (2) methyl,
- (3) hydroxyl,
- (4) halogen, and
- (5) -CN;

each R<sup>a</sup> is independently selected from:

- (1) -OR<sup>c</sup>,

- (2) halogen,
- (3)  $-S(O)_mR^c$ ,
- (4)  $-NR^cR^d$ ,
- (5)  $-C(O)R^c$ ,
- (6)  $-CO_2R^c$ , and
- (7) oxo;

or a pharmaceutically acceptable salt thereof.

Claim 6 (Original): The compound according to Claim 5 wherein:

$R^1$  and  $R^2$  are independently selected from:

- (1) phenyl,
- (2) 4-fluorophenyl,
- (3) 2-chlorophenyl,
- (4) 3-chlorophenyl,
- (5) 4-chlorophenyl,
- (6) 4-cyanophenyl,
- (7) 4-methylphenyl,
- (8) 4-isopropylphenyl,
- (9) 4-biphenyl,
- (10) 4-bromophenyl,
- (11) 4-iodophenyl,
- (12) 2,4-dichlorophenyl, and
- (13) 2-chloro-4-fluorophenyl;

or a pharmaceutically acceptable salt thereof.

Claim 7 (Original): The compound according to Claim 6 wherein:

$R^1$  and  $R^2$  are independently selected from phenyl and 4-chlorophenyl;

$R^3$  is methyl, wherein methyl is optionally substituted with one to three substituents independently selected from  $R^a$ ;

or a pharmaceutically acceptable salt thereof.

Claim 8 (Original): A compound selected from:


- (1) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzofuran-2-carboxamide;

- (2) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-3-chloro-2-naphthamide;
- (3) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isoxazole-5-carboxamide;
- (4) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrido[3,2-*b*]pyridine-2-carboxamide;
- (5) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazole-3-carboxamide;
- (6) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-thiazole-5-carboxamide;
- (7) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-nicotinamide;
- (8) 2-(1-tetrazolyl)-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (9) 3-(1-tetrazolyl)-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (10) 4-(1-tetrazolyl)-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (11) 5-methyl-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-thiazole-4-carboxamide;
- (12) 2-phenyl-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (13) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazine-2-carboxamide;
- (14) 3-(1-(3,5-dimethyl-pyrazolyl))-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (15) 4-(1-(pyrrolidin-2-one))-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (16) 3-(1-(imidazolidin-2-one))-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (17) 4-phenyl-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (18) 6-bromo-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-picolinamide;
- (19) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isonicotinamide;
- (20) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-picolinamide;
- (21) 4-methyl-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,2,5-oxadiazole-3-carboxamide;
- (22) 3-(1-(pyrrolidin-2-one))-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (23) 2-bromo-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isonicotinamide;
- (24) 3-phenyl-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (25) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrimidine-4-carboxamide;
- (26) 4-(1-pyrazolyl)-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (27) 2-(1-pyrazolyl)-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (28) 5,6,7,8-tetrahydro-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-carbazole-3-carboxamide;
- (29) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1*H*-quinazolin-2-one-4-carboxamide;
- (30) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzoxazole-2-carboxamide;
- (31) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazolo[2,3-*a*]pyrimidine-6-carboxamide;
- (32) 2,4-dimethyl-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazolo[2,3-*a*]pyrimidine-6-carboxamide;
- (33) 4-(1-piperidiny)-*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

- (34) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrimidine-5-carboxamide;
- (35) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrido(1,2-a)pyrimidine-4-one-5-carboxamide;
- (36) 4,5,6,7-tetrahydro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-indazole-3-carboxamide;
- (37) 5-fluoro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzimidazole-2-carboxamide;
- (38) 5-phenyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazole-3-carboxamide;
- (39) 1,2,3,4-tetrahydro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,8-naphthyridine-7-carboxamide;
- (40) 1-methyl-3-ethyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazole-5-carboxamide;
- (41) 1-methyl-3-propyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazole-5-carboxamide;
- (42) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-quinoline-5-carboxamide;
- (43) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-imidazo(1,2-a)pyridine-2-carboxamide;
- (44) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-quinoline-4-carboxamide;
- (45) 4-bromo-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-nicotinamide;
- (46) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isoquinoline-8-carboxamide;
- (47) 3-bromo-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-picolinamide;
- (48) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isoquinoline-5-carboxamide;
- (49) 4-(2-formyl-phenyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (50) 4-(2-hydroxymethyl-phenyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (51) 4-(2-aminophenyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (52) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2(3H)-imidazolone-4-carboxamide;
- (53) 3-(1-tetrazolyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isonicotinamide;
- (54) 3,4-(ethylenedioxy)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-thiophene-2-carboxamide;
- (55) 1-isopropyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazole-4-carboxamide;
- (56) 5-bromo-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-picolinamide;
- (57) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,8-naphthyridine-2-carboxamide;
- (58) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzothiazole-2-carboxamide;
- (59) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzimidazole-2-carboxamide;
- (60) 5-chloro-2-(2-(1-pyrrolyl)ethyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (61) 2-(2-phenylethyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (62) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-naphthylene-2-carboxamide;
- (63) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-quinoline-5-carboxamide;
- (64) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-naphthylene-1-carboxamide;
- (65) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
- (66) 2-chloro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

- (67) 3-chloro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
  - (68) 4-chloro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
  - (69) 3,5-dichloro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isonicotinamide;
  - (70) N-[2-(3-pyridyl)-3-(4-chlorophenyl)-1-methylpropyl]-benzamide;
  - (71) N-[2-(2-pyridyl)-3-(4-chlorophenyl)-1-methylpropyl]-benzamide;
  - (72) N-[2-(4-pyridyl)-3-(4-chlorophenyl)-1-methylpropyl]-benzamide; and
  - (73) N-[3-(3-chloro-2-pyridyl)-2-phenyl-1-methylpropyl]-benzamide;
- or a pharmaceutically acceptable salt thereof.

Claim 9 (currently amended): A compound of structural formula IA:



(IA)

or a pharmaceutically acceptable salt thereof, wherein:

R<sup>1</sup> is selected from:

- (1) aryl, and
- (2) heteroaryl,

wherein aryl and heteroaryl are optionally substituted on the carbon or nitrogen with one to four substituents independently selected from R<sup>b</sup>;

R<sup>2</sup> is selected from:

- (1) aryl, and
- (2) heteroaryl,

wherein aryl and heteroaryl are optionally substituted on the carbon or nitrogen with one to four substituents independently selected from R<sup>b</sup>;

R<sup>3</sup> is selected from:

- (1) hydrogen, and
- (2) C<sub>1-4</sub>alkyl,

wherein alkyl is optionally substituted with one to four substituents independently selected from R<sup>a</sup>;

Ar<sup>1</sup> is selected from:

- (1) aryl, and
- (2) heteroaryl,

each optionally substituted on the carbon or nitrogen with one, two, or three groups independently selected from R<sup>b</sup>;

each R<sup>a</sup> is independently selected from:

- (1) -OR<sup>c</sup>,
- (2) -NR<sup>c</sup>S(O)<sub>m</sub>R<sup>d</sup>,
- (3) -NO<sub>2</sub>,
- (4) halogen,
- (5) -S(O)<sub>m</sub>R<sup>c</sup>,
- (6) -SR<sup>c</sup>,
- (7) -S(O)<sub>2</sub>OR<sup>c</sup>,
- (8) -S(O)<sub>m</sub>NR<sup>c</sup>R<sup>d</sup>,
- (9) -NR<sup>c</sup>R<sup>d</sup>,
- (10) -O(CR<sup>e</sup>R<sup>f</sup>)<sub>n</sub>NR<sup>c</sup>R<sup>d</sup>,
- (11) -C(O)R<sup>c</sup>,
- (12) -CO<sub>2</sub>R<sup>c</sup>,
- (13) -CO<sub>2</sub>(CR<sup>e</sup>R<sup>f</sup>)<sub>n</sub>CONR<sup>c</sup>R<sup>d</sup>,
- (14) -OC(O)R<sup>c</sup>,
- (15) -CN,
- (16) -C(O)NR<sup>c</sup>R<sup>d</sup>,
- (17) -NR<sup>c</sup>C(O)R<sup>d</sup>,
- (18) -OC(O)NR<sup>c</sup>R<sup>d</sup>,
- (19) -NR<sup>c</sup>C(O)OR<sup>d</sup>,
- (20) -NR<sup>c</sup>C(O)NR<sup>c</sup>R<sup>d</sup>,
- (21) -CR<sup>c</sup>(N-OR<sup>d</sup>),
- (22) CF<sub>3</sub>,
- (23) -OCF<sub>3</sub>,
- (24) C<sub>3-8</sub>cycloalkyl,
- (25) cycloheteroalkyl, and
- (26) oxo;

each R<sup>b</sup> is independently selected from:



- (1)  $R^a$ ,
- (2)  $C_{1-10}$ alkyl,
- (3)  $C_{3-8}$ cycloalkyl,
- (4) cycloheteroalkyl,
- (5) aryl,
- (6) aryl $C_{1-4}$ alkyl,
- (7) heteroaryl, and
- (8) heteroaryl $C_{1-4}$ alkyl,

wherein alkyl, cycloalkyl, cycloheteroalkyl, and heteroaryl are optionally substituted with oxo, and

wherein aryl and heteroaryl are optionally substituted with  $-OR^c$ ,  $NR^cR^d$ , or  $-C(O)R^c$ ;

$R^c$  and  $R^d$  are independently selected from:

- (1) hydrogen,
- (2)  $C_{1-10}$ alkyl,
- (3)  $C_{2-10}$  alkenyl,
- (4)  $C_{2-10}$ alkynyl,
- (5) cycloalkyl,
- (6) cycloalkyl- $C_{1-10}$ alkyl,
- (7) cycloheteroalkyl,
- (8) cycloheteroalkyl- $C_{1-10}$  alkyl;
- (9) aryl,
- (10) heteroaryl,
- (11) aryl- $C_{1-10}$ alkyl, and
- (12) heteroaryl- $C_{1-10}$ alkyl, or

$R^c$  and  $R^d$  together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

or two  $-OR^c$  groups together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

each  $R^c$  and  $R^d$  may be unsubstituted or substituted with one to three substituents selected from  $R^h$ ;

$R^e$  and  $R^f$  are independently selected from:

- (1) hydrogen,
- (2)  $C_{1-10}$ alkyl,
- (3)  $C_{2-10}$  alkenyl,
- (4)  $C_{2-10}$ alkynyl,

- (5) cycloalkyl,
- (6) cycloalkyl-C<sub>1-10</sub> alkyl,
- (7) cycloheteroalkyl,
- (8) cycloheteroalkyl-C<sub>1-10</sub> alkyl,
- (9) aryl,
- (10) heteroaryl,
- (11) arylC<sub>1-10</sub> alkyl, and
- (12) heteroarylC<sub>1-10</sub> alkyl, or

R<sup>e</sup> and R<sup>f</sup> together with the carbon to which they are attached form a ring of 5 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

each R<sup>g</sup> is independently selected from

- (1) C<sub>1-10</sub>alkyl,
- (2) C<sub>3-8</sub>cycloalkyl,
- (3) cycloheteroalkyl,
- (4) aryl,
- (5) arylC<sub>1-4</sub>alkyl,
- (6) heteroaryl,
- (7) heteroarylC<sub>1-4</sub>alkyl,
- (8) -S(O)<sub>m</sub>R<sup>e</sup>,
- (9) -C(O)R<sup>e</sup>,
- (10) -CO<sub>2</sub>R<sup>e</sup>,
- (11) -CO<sub>2</sub>(C(R<sup>e</sup>R<sup>f</sup>)<sub>n</sub>CONR<sup>e</sup>R<sup>f</sup>, and
- (12) -C(O)NR<sup>e</sup>R<sup>f</sup>;

each R<sup>h</sup> is independently selected from:

- (1) C<sub>1-10</sub>alkyl,
- (2) C<sub>3-8</sub>cycloalkyl,
- (3) cycloheteroalkyl,
- (4) aryl,
- (5) arylC<sub>1-4</sub>alkyl,
- (6) heteroaryl,
- (7) heteroarylC<sub>1-4</sub>alkyl,
- (8) -OR<sup>e</sup>,
- (9) -NR<sup>e</sup>S(O)<sub>m</sub>R<sup>f</sup>,

provided that when R<sup>1</sup> and R<sup>2</sup> are unsubstituted aryl or unsubstituted heteroaryl, and R<sup>3</sup> is ~~hydrogen or~~ C 1-4 alkyl, Ar<sup>1</sup> is substituted with at least one R<sup>b</sup> substituent; and

provided that when R<sup>1</sup> is selected from the group consisting of unsubstituted phenyl, *para*-chlorophenyl or *para*-methoxy phenyl, R<sup>2</sup> is unsubstituted phenyl, and R<sup>3</sup> is -CH<sub>3</sub>, Ar<sup>1</sup> is not unsubstituted phenyl, *ortho*-CO<sub>2</sub>H monosubstituted phenyl, or 3,4-dimethoxy phenyl.

Claim 10 (Original): The compound according to Claim 9 wherein:

R<sup>1</sup> and R<sup>2</sup> are independently selected from:

- (1) phenyl,
- (2) naphthyl, and
- (3) pyridyl,

each optionally substituted with one to four substituents independently selected from R<sup>b</sup>; or a pharmaceutically acceptable salt thereof.

Claim 11 (Original): The compound according to Claim 10 wherein:

Ar<sup>1</sup> is selected from:

- (1) phenyl,
- (2) naphthyl,
- (3) thienyl,
- (4) furanyl,
- (5) pyrrolyl,
- (6) oxazolyl,
- (7) isoxazolyl,
- (8) 1,2,5-oxadiazolyl,
- (9) 1,2,5-thiadiazolyl,
- (10) thiazolyl,
- (11) pyrazolyl,
- (12) triazolyl,
- (13) tetrazolyl,
- (14) benzothienyl,
- (15) benzofuranyl,
- (16) benzoxazolyl,

- (10)  $-S(O)_mRe$ ,
- (11)  $-SRe$ ,
- (12)  $-S(O)_2OR^e$ ,
- (13)  $-S(O)_mNR^eR^f$ ,
- (14)  $-NR^eR^f$ ,
- (15)  $-O(CR^eR^f)_nNR^eR^f$ ,
- (16)  $-C(O)R^e$ ,
- (17)  $-CO_2R^e$ ,
- (18)  $-CO_2(CR^eR^f)_nCONR^eR^f$ ,
- (19)  $-OC(O)R^e$ ,
- (20)  $-CN$ ,
- (21)  $-C(O)NR^eR^f$ ,
- (22)  $-NR^eC(O)R^f$ ,
- (23)  $-OC(O)NR^eR^f$ ,
- (24)  $-NR^eC(O)OR^f$ ,
- (25)  $-NR^eC(O)NR^eR^f$ ,
- (26)  $CF_3$ , and
- (27)  $-OCF_3$ ,

m is selected from 1 and 2; and

n is selected from 1, 2, and 3;

provided that when  $R^1$  is phenyl, naphthyl, or heteroaryl,  $R^2$  is phenyl and  $R^3$  is hydrogen,  $Ar^1$  is not unsubstituted phenyl and is not mono, di or tri-substituted phenyl with an  $R^b$ -substituent selected from the group consisting of halogen, hydroxy,  $C_{1-6}$  alkyl, phenyl, CN,  $NO_2$ ,  $CO_2H$ ,  $C(O)C_{1-6}$  alkyl,  $CO_2C_{1-6}$  alkyl,  $-C(O)NH_2$ ,  $-C(O)NH$  heterocycloalkyl,  $NH_2$ ,  $NH$  heterocycloalkyl, furanyl, dihydrofuranyl, pyrrolidyl, dihydropyrrolidyl, and 1,3-dioxolan; and

provided that when  $R^1$  is aryl, monosubstituted with halogen,  $OCH_3$  or  $CH_3$  and optionally di-substituted with halogen,  $R^2$  is aryl, optionally mono or di-substituted with halogen, and  $R^3$  is hydrogen,  $Ar^1$  is not unsubstituted 4-pyridinyl; and

- (17) benzimidazolyl,
- (18) benzothiazolyl,
- (19) indanyl,
- (20) indenyl,
- (21) indolyl,
- (22) imidazo[1,2-a]pyridinyl,
- (23)  $\beta$ -carbolinyl,
- (24) 5,6,7,8-tetrahydro- $\beta$ -carbolinyl,
- (25) tetrahydronaphthyl,
- (26) 4,5,6,7-tetrahydroindazolyl,
- (27) 2,3-dihydrobenzofuranyl,
- (28) dihydrobenzopyranyl,
- (29) 1,4-benzodioxanyl,
- (30) pyridinyl,
- (31) pyrimidinyl,
- (32) pyrazinyl,
- (33) quinolinyl,
- (34) isoquinolinyl,
- (35) quinazolonyl,
- (36) quinazolinyl,
- (37) 1,8-naphthyridinyl,
- (38) 1,2,3,4-tetrahydro-1,8-naphthyridinyl,
- (39) pyrido[3,2-b]pyridinyl,
- (40) pyrazolo[2,3-a]pyrimidinyl,
- (41) pyrido[1,2-a]pyrimidinyl,
- (42) pyrido[1,2-a]pyrimidonyl,
- (43) benzopyrimidinyl,
- (44) imidazolyl, and
- (45) imidazolonyl,

each optionally substituted with one, two, or three groups independently selected from R<sup>b</sup>;  
or a pharmaceutically acceptable salt thereof.

Claim 12 (currently amended ): The compound of claim 11 wherein:

R<sup>3</sup> is selected from:

- (1) ~~hydrogen, and~~
- (2) C<sub>1-4</sub>alkyl,

wherein alkyl is optionally substituted with one to four substituents independently selected from R<sup>a</sup>;

Ar<sup>1</sup> is selected from:

- (1) phenyl,
- (2) naphthyl,
- (3) thienyl,
- (4) isoxazolyl,
- (5) 1,2,5-oxadiazolyl,
- (6) thiazolyl,
- (7) pyrazolyl,
- (8) triazolyl,
- (9) tetrazolyl,
- (10) benzofuranyl,
- (11) benzoxazolyl,
- (12) benzimidazolyl,
- (13) benzothiazolyl,
- (14) imidazo[1,2-a]pyridinyl,
- (15) 5,6,7,8-tetrahydro- $\beta$ -carbolinyl,
- (16) 4,5,6,7-tetrahydroindazolyl,
- (17) pyridinyl,
- (18) pyrimidinyl,
- (19) pyrazinyl,
- (20) quinolinyl,
- (21) isoquinolinyl,
- (22) quinazolonyl,
- (23) quinazolinyl,
- (24) 1,8-naphthyridinyl,
- (25) 1,2,3,4-tetrahydro-1,8-naphthyridinyl,
- (26) pyrido[3,2-b]pyridinyl,
- (27) pyrazolo[2,3-a]pyrimidinyl,
- (28) pyrido[1,2-a]pyrimidinyl,

(29) pyrido[1,2-a]pyrimidonyl,

(30) benzopyrimidinyl,

(31) imidazolyl, and

(32) imidazolonyl,

each optionally substituted with one, two, or three groups independently selected from R<sup>b</sup>;

each R<sup>a</sup> is independently selected from:

(1) -OR<sup>c</sup>,

(2) halogen,

(3) -S(O)<sub>m</sub>R<sup>c</sup>,

(4) -SR<sup>c</sup>,

(5) -S(O)<sub>2</sub>OR<sup>c</sup>,

(6) -S(O)<sub>m</sub>NR<sup>c</sup>R<sup>d</sup>,

(7) -NR<sup>c</sup>R<sup>d</sup>,

(8) -C(O)R<sup>c</sup>,

(9) -CO<sub>2</sub>R<sup>c</sup>,

(10) -CN,

(11) -C(O)NR<sup>c</sup>R<sup>d</sup>,

(12) CF<sub>3</sub>,

(13) -OCF<sub>3</sub>,

(14) C<sub>3-8</sub>cycloalkyl,

(15) cycloheteroalkyl, and

(16) oxo;

each R<sup>b</sup> is independently selected from:

(1) R<sup>a</sup>,

(2) C<sub>1-10</sub>alkyl,

(3) cycloheteroalkyl,

(4) aryl,

(5) arylC<sub>1-4</sub>alkyl,

(6) heteroaryl, and

(7) heteroarylC<sub>1-4</sub>alkyl,

wherein alkyl, cycloalkyl, cycloheteroalkyl, heteroaryl are optionally substituted with oxo, and

wherein aryl and heteroaryl are optionally substituted with -OR<sup>c</sup>, NR<sup>c</sup>R<sup>d</sup>, or -C(O)R<sup>c</sup>;

R<sup>c</sup> and R<sup>d</sup> are independently selected from:

- (1) hydrogen,
- (2) C<sub>1-10</sub>alkyl,
- (3) cycloalkyl,
- (4) cycloheteroalkyl,
- (5) aryl,
- (6) heteroaryl, or

R<sup>c</sup> and R<sup>d</sup> together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R<sup>g</sup>,  
or two -OR<sup>c</sup> groups together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R<sup>g</sup>,  
each R<sup>c</sup> and R<sup>d</sup> may be unsubstituted or substituted with one to three substituents selected from R<sup>h</sup>,  
or a pharmaceutically acceptable salt thereof.

Claim 13 (Original): The compound according to Claim 12, wherein:

R<sup>1</sup> and R<sup>2</sup> are independently selected from:

- (1) phenyl, and
- (2) pyridyl,

each optionally substituted with one to four substituents independently selected from R<sup>b</sup>;

R<sup>3</sup> is C<sub>1-4</sub>alkyl, wherein alkyl is optionally substituted with one to four substituents independently selected from R<sup>a</sup>;

each R<sup>a</sup> is independently selected from:

- (1) -OR<sup>c</sup>,
- (2) halogen,
- (3) -S(O)<sub>m</sub>R<sup>c</sup>,
- (4) -NR<sup>c</sup>R<sup>d</sup>,
- (5) -C(O)R<sup>c</sup>,
- (6) -CO<sub>2</sub>R<sup>c</sup>, and
- (7) oxo;

or a pharmaceutically acceptable salt thereof.

Claim 14 (Original): The compound according to Claim 13, wherein:

R<sup>1</sup> and R<sup>2</sup> are independently selected from:

- (1) phenyl,



- (2) 4-fluorophenyl,
- (3) 2-chlorophenyl,
- (4) 3-chlorophenyl,
- (5) 4-chlorophenyl,
- (6) 4-cyanophenyl,
- (7) 4-methylphenyl,
- (8) 4-isopropylphenyl,
- (9) 4-biphenyl,
- (10) 4-bromophenyl,
- (11) 4-iodophenyl,
- (12) 2,4-dichlorophenyl, and
- (13) 2-chloro-4-fluorophenyl;

or a pharmaceutically acceptable salt thereof.

Claim 15 (Original): The compound according to Claim 14 wherein:

R<sup>1</sup> and R<sup>2</sup> are independently selected from phenyl and 4-chlorophenyl;

R<sup>3</sup> is methyl, wherein methyl is optionally substituted with one to three substituents independently selected from R<sup>a</sup>;

or a pharmaceutically acceptable salt thereof.

Claim 16 (Original): A composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.

Claim 17 (Original): A composition comprising a compound according to Claim 8 and a pharmaceutically acceptable carrier.

Claim 18 (Original): A method of preventing obesity in a person at risk for obesity comprising administration to said person of about 0.001 to about 100 mg/kg of a compound according to Claim 1.

Claim 19 (Original): A method of preventing obesity in a person at risk for obesity comprising administration to said person of about 0.001 to about 100 mg/kg of a compound according to Claim 8.

Claim 20 (Original): A method of treating a disease mediated by the Cannabinoid-1 receptor comprising administration of a therapeutically effective amount of a compound of Claim 1 to a patient in need of such treatment.

Claim 21 (Original): The method according to Claim 20 wherein the disease mediated by the Cannabinoid-1 receptor is selected from: psychosis, memory deficit, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, schizophrenia, substance abuse disorders, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, asthma, obesity, and other eating disorders associated with excessive food intake.

Claim 22 (Original): The method according to Claim 21 wherein the disease mediated by the Cannabinoid-1 receptor is an eating disorder associated with excessive food intake.

Claim 23 (Original): The method according to Claim 22 wherein the eating disorder associated with excessive food intake is selected from obesity, bulimia nervosa, and compulsive eating disorders.

Claim 24 (Original): The method according to Claim 23 wherein the eating disorder associated with excessive food intake is obesity.

Claims 25-30 (Cancelled).